Betashares Global Healthcare Currency Hedged ETF

About DRUG

Find out what a historical investment in Betashares Global Healthcare Currency Hedged ETF would be worth today using our DRUG stock calculator.

Market Capitalisation

$0

Price-earnings ratio

0

Dividend yield

0.00%

High today

$9.38

Low today

$9.29

Open price

$9.38

52-week high

-

52-week low

-

Ready to start your investing journey with Stake?

Open an account

Announcements




What is DRUG stock?

DRUG is an exchange-traded fund that invests in large-cap healthcare companies outside of Australia, both directly and through foreign currency forward contracts. 

Also known as BetaShares Global Healthcare ETF - Currency Hedged, DRUG is actively managed by BetaShares Capital Limited. It seeks to replicate the behaviour of the Nasdaq Global ex-Australia Healthcare Hedged AUD Index by investing in companies as per their weight in the index. DRUG’s returns are hedged to the Australian dollar.

Why is DRUG a currency-hedged ETF?

DRUG ETF is denominated in Australian dollars but equities within the fund are in foreign currencies.

By currency hedging, BetaShares locks down a set exchange rate for the future and lowers the effects and risks of exchange rate fluctuations on investments within DRUG.

How do I buy DRUG stock?

Stake offers a quick and easy way to purchase the DRUG ETF – along with 2,000+ other Australian stocks and ASX ETFs – for a brokerage fee of only A$3.

Stake is CHESS sponsored, meaning that when you invest in ASX stocks, you get a HIN (Holder Identification Number) and stocks are held in your name.

With Stake, you can be in the market in under 5 minutes, whether it's the ASX or Wall St. If you’re interested in building your portfolio by adding DRUG, sign up today.

Which stocks are in the DRUG ETF?

73.9% of DRUG is allocated to American healthcare stocks. Swiss, British, Japanese and Danish healthcare companies are also sizeable allocations at 9.4%, 4.9%, 3.3% and 3.2%, respectively.

Some of DRUG’s most prominent holdings include UnitedHealth Group Incorporated (UNH), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Pfizer Inc. (PFE), Roche (ROG), Eli Lilly & Company (LLY), Thermo Fisher Scientific (TMO), AstraZeneca (AZN), Novo Nordisk (NOVO-B) and Takeda Pharmaceutical Company (4502).

For a complete list of DRUG’s current holdings, click here.

Does DRUG pay a distribution?

Yes. As of 31 March 2022, DRUG stock’s distribution yield is 4.7%.

In FY2021, Betashares paid out a total of A$0.36644 per share. Historically, distributions have been paid twice a year, usually in January and July.

Is DRUG a good buy?

DRUG may be an appropriate buy for investors seeking quick, simple and cost-effective access to the world’s biggest healthcare companies. By purchasing DRUG, investors do not need to purchase individual healthcare stocks.

ETFs are usually considered long-term passive investments and the DRUG ETF is no exception. The fund has a low management cost of 0.57% p.a. In FY2021, the DRUG stock price achieved 22.34% growth.

Buying DRUG shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Betashares Global Healthcare Currency Hedged ETF in minutes.
  1. Sign up with some I.D. and zero paperwork
  2. Add funds to your account
  3. Make your first investment in DRUG

The ticker symbol for Betashares Global Healthcare Currency Hedged ETF is DRUG.

One share of DRUG is valued at $9.31 as of 21 November 2026.

The Betashares Global Healthcare Currency Hedged ETF 52-week high stock price is $NaN.

The Betashares Global Healthcare Currency Hedged ETF 52-week low stock price is $NaN.

Yes, the Stake investing platform allows you to buy DRUG shares and over 13,000 more stocks and ETFs across the ASX and Wall St.

This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Stake app

Invest in DRUG on Stake

  • Buy DRUG from A$3 brokerage
  • Invest in 2,500+ Aussie stocks and ETFs
  • CHESS-sponsored ASX trades
Get started

Stock shown for demonstrative purposes only. A$3 brokerage up to A$30,000.

Explore Stake


Made in Australia

Sydney, Australia


Get the app

Scan QR code to download the app

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The Stake Accumulate Fund (ARSN 680 653 374) is issued by K2 Asset Management Ltd (ABN 95 085 445 094 AFSL 244 393), a wholly owned subsidiary of K2 Asset Management Holdings Ltd (ABN 59 124 636 782). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services Guide, Terms & Conditions, Privacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

This information is being provided in connection with the Australian retail offer component of the initial public offering of shares of Class A common stock (“Shares”) in Anthropic, PBC (“Anthropic”) (“IPO”). The Australian retail offer is an offer of newly issued Shares by Anthropic (“Australian Retail Offer”) made under the Australian prospectus lodged with the Australian Securities and Investments Commission on 11 November 2026 (“Australian Prospectus”). This information does not form part of the Australian Prospectus, and anyone considering applying for Shares under the Australian Retail Offer should rely only on information in the Australian Prospectus and any supplementary or replacement Australian Prospectus. A copy of the Australian Prospectus is available on ipo.anthropic.com. Further information about Anthropic, the IPO, the Shares and the risks of investing in Anthropic is set out in the Australian Prospectus. Anyone considering applying for Shares under the Australian Retail Offer should read and consider the Australian Prospectus in full in deciding whether to acquire Shares under the Australian Retail Offer. Anyone who wants to acquire Shares under the Australian Retail Offer will need to complete the application form that accompanies the Australian Prospectus, in accordance with the process set out in the Australian Prospectus and any other instructions from their broker. Anthropic has applied to list its Class A common stock on the Nasdaq Global Select Market under the symbol “ANT”. Anthropic will not be applying for listing on the Australian Securities Exchange.

Us securities law disclaimer

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (“SEC”) but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to its acceptance after the effective date. The prospectus in the registration statement and other documents Anthropic has filed with the SEC include additional information about Anthropic and the offering. Investors may get these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. The registration statement (including the US prospectus) is available at www.sec.gov

Copyright © 2026 Stake. All rights reserved.